Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 furmonertinib versus platinum-pemetrexed as first-line treatment for EGFR exon 20 insertion non-squamous NSCLC
CTR20231409Phase 3Active
- Sponsor
- Allist Pharmaceuticals
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furmonertinib in non-small cell lung cancer (NSCLC), Non-small cell lung cancer (NS-NSCLC), sponsored by Allist Pharmaceuticals. Started Aug 2023; status: active.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20231409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231409.